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The therapeutic effect of aspirin on vein graft patency was
studied in patients undergoing coronary artery bypass graft
surgery. The study design enabled the prospective evalua-
tion of the relation of platelet activation, as measured by
plasma beta-thromboglobulin concentration, to subsequent
coronary vein graft occlusion. Serial beta-thromboglobulin
levels were measured in 105 patients randomized to receive
aspirin (324 mg/day) or placebo beginning within 1 h after
surgery. Graft patency was assessed angiographically at 1
week and 1 year after surgery.
Of 49 patients receiving placebo, 17 (34.7%) had one or
more graft occlusions, 6 early, 10 late and 1with both early
and late occlusion. Of 56 patients receiving aspirin, 7
(12.5%) had one or more occlusions, 3early and 4 late (p <
0.01). Preoperatively, the beta-thromboglobulin level in
surgical patients (29 ± 13.5 ng/ml) was significantly higher
than that of 51 control subjects (22.6 ± 11.1 ng/ml) (p <
0.004).
Plasma beta-thromboglobulin levels remained compar-
Enhanced platelet reactivity has been well documented in
various manifestations ofcoronary atherosclerosis. Elevated
plasma levels of the platelet-secreted proteins (beta-
thromboglobulin and platelet factor 4) have been found in
patients with chronic (1-3) and unstable (4,5) angina and
after myocardial infarction (6,7). Similarly, shortened plate-
From the "Departments of Cardiology, Cardiovascular Surgery and
Haematology, St. Vincent's Hospital, Sydney, New South Wales, Australia,
tUniversity of New South Wales School of Medicine, St. George Hospital.
Sydney and tStatistical Laboratory, Macquarie University, Sydney. This
study was supported in part by grants-in-aid from the National Heart
Foundation of Australia, National Health and Medical Research Council and
Bayer Australia, Ltd., Sydney.
Manuscript received July 29, 1989; revised manuscript received Novem-
ber 6, 1989, accepted December 21, 1989.
Address for reprints: Thomas P. Gavaghan, MBBS, 22 Fisher Road, Dee
Why, New South Wales 2099, Australia.
©1990 by the American College of Cardiology
atively constant at 3 and 12 months after surgery in the 43
patients who had both samples available (p < 0.001, r =
0.65). The reduction in beta-thromboglobulin concentra-
tion from the preoperative level to 12 months postopera-
tively was greater in the aspirin-treated group (p < 0.001).
Multivariate logistic regression analysis demonstrated a
significant association between preoperative beta-thrombo-
globulin concentration and graft occlusion (p < 0.02), and
aspirin treatment was effective in preventing occlusion
when adjusted for the preoperative beta-thromboglobulin
level (p < 0.005).
Plasma beta-thromboglobulin concentrations are ele-
vated in patients with coronary artery disease, suggesting
ongoing platelet activation. The risk of coronary artery
bypass graft occlusion is greater in patients with higher
preoperative levels of beta-thromboglobulin, a risk that is
greatly reduced by aspirin therapy begun within 1 h after
surgery and continued for 12 months postoperatively.
(J Am Coli CardioI1990;15:1250-8)
let survival time and the presence of circulating platelet
aggregates have been reported in patients with coronary
artery disease (3,8,9). The normalization of these indexes of
platelet function in the presence of vascular disease has been
shown to occur both after coronary revascularization (10)
and with antiplatelet therapy (3,11). Some studies, however,
have failed to confirm these findings (12,13), and others have
found no significant difference in platelet survival (14) or
plasma levels of beta-thromboglobulin (IS) between patients
with coronary artery disease and normal control subjects.
There are few published data (5,6) concerning the prognostic
value of these measurements of platelet reactivity in patients
with coronary artery disease. Nevertheless, several studies
have shown the benefit of antiplatelet therapy in maintaining
graft patency after bypass surgery (16-20), reducing the
incidence of acute myocardial infarction and death in pa-
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tients with unstable angina (21) and delaying the progression
of peripheral arterial disease (22),
The occlusion of saphenous vein bypass grafts within the
first postoperative year is predominantly a result of throm-
bosis and diffuse intimal hyperplasia. Both these processes
appear to be platelet-mediated (23). Although elevated beta-
thromboglobulin may be regarded as a nonspecific index of
platelet activation, this prospective study was undertaken to
show whether there is a significant relation between preoper-
ative plasma beta-thromboglobulin concentration and the
occlusion of saphenous vein bypass grafts in a randomized
placebo-controlled trial of aspirin therapy after coronary
artery bypass surgery. A relation between anticardiolipin
antibodies and graft occlusion was previously reported in a
preliminary analysis of the first 83 patients studied (24).
Methods
Study patients. From August 1984 through October 1985,
383 patients undergoing primary aortocoronary saphenous
vein bypass grafting at St. Vincent's Hospital were screened
for entry into a prospective, randomized, double-blind,
placebo-controlled trial of aspirin for prevention of graft
occlusion during the first postoperative year; 138 patients
(36%) were considered eligible under the protocol and 137
patients consented to participate in the study. Criteria for
exclusion from the study included age >70 years (n = 35),
use of platelet inhibiting or antiinflammatory drugs within 7
days before surgery (n = 70), contraindications to aspirin
therapy (n = 42), other vascular disease likely to require
antithrombotic treatment (n = 35), presence of insulin-
dependent diabetes mellitus (n = 19), coexistent connective
tissue or other autoimmune disease (n = 5), nonfluency in
English preventing an adequate explanation of need for
follow-up angiography and tablet compliance (n = 3) and
miscellaneous factors including history of noncompliance,
significant renal impairment (creatinine >0.15 mmolliiter),
isolated internal mammary artery grafting, severe peripheral
vascular disease and severe left ventricular dysfunction with
ejection fraction <20% precluding safe repeat angiography
(n = 37).
Study protocol. After informed consent was obtained
before surgery, patients were assigned to therapy in a
randomized double-blind fashion. The randomization
scheme involved a series of computer-generated random
numbers, and patients were randomized by the dispensing
pharmacist and stratified by each of five surgeons. Of the 137
patients entered into the study, 68 were assigned to aspirin
therapy and 69 to placebo. The protocol conformed to the
National Health and Medical Research Council guidelines
for human experimentation and was approved by the Ethics
and Research Committee of St. Vincent's Hospital.
The study medication consisted of soluble aspirin (324
mg) or a matching placebo tablet to be commenced I h after
leaving the operating theater and daily thereafter. The med-
ication was dissolved in 30 ml of water and given by
nasogastric tube (90 min clamp time) and repeated daily until
the patient could tolerate oral intake.
Surgery. Cardiopulmonary bypass was established and
myocardial preservation was effected by means of multiple
dose cold blood cardioplegia (5° to 7°C) and systemic cooling
to 24° to 2rc. Saphenous veins were carefully resected,
gently distended with heparinized whole blood and stored in
blood until implantation. Distal anastomoses were per-
formed with 7-0 and proximal anastomoses with 5-0 Prolene
sutures during rewarming. Grafts were constructed as single
grafts, sequential grafts or occasionally branched Y grafts.
Coronary endarterectomy was performed in diffusely dis-
eased distal arteries at the discretion of the surgeon. Patients
were given heparin at the commencement of cardiopulmo-
nary bypass, and this was promptly reversed with protamine
sulfate before removal of the aortic cannula. Blood loss and
transfusion requirements were recorded for both treatment
groups.
Beta-thromboglobulin studies. Venous blood (4.5 ml) was
drawn through a 21 gauge scalp vein needle, avoiding stasis
and after the first 3 ml was discarded. The blood was mixed
with 0.5 ml of an ethylenediaminetetraacetic acid (EDTA)-
theophylline-prostaglandin EI mixture (25) in a precooled
tube, placed directly on ice and then centrifuged within 30
min at 4°C in a "Hettich" Mikroliter centrifuge (model 2020)
at 8,000 g for 5 min. The top half of the plasma column was
transferred to another precooled tube and centrifuged at
8,000 g for a further 5 min. The upper 1.5 ml of plasma was
aspirated and stored at -70°C for assay. Radioimmunoassay
of beta-thromboglobulin was carried out using a solid phase
system in microtiter wells with a "sandwich" of goat anti-
rabbit immunoglobin (Ig) (Fe-specific), rabbit anti-beta-
thromboglobulin serum and indium-125-labeled beta-
thromboglobulin. The assay was calibrated with World
Health Organization 1st International standard beta-
thromboglobulin, and all assays were carried out using both
undiluted and a 1:2 dilution of plasma to ensure parallelism.
All plasma samples from each individual patient were proc-
essed in one assay to avoid error from interassay variation.
The within assay and between assay coefficient of variation
was 6.8% and 10.7%, respectively, calculated from duplicate
standards of 25 IV of beta-thromboglobulin included in each
of seven assays.
Plasma beta-thromboglobulin concentrations > 100 ng/ml
were regarded as likely to be affected by artifactual in vitro
platelet granule release and were excluded before analysis.
There were six such assay results: two A samples, 127 and
718 ng/ml, respectively; two B samples, 234 and 419 ng/ml,
respectively; and two D samples, 117 and 515 ng/ml, respec-
tively.
Ofthe 137 patients entered into the study, 105 had at least
two serial blood samples for beta-thromboglobulin assay. In
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the remaining 32 patients, only a single preoperative sample
or no sample was collected as a result of logistic problems
with preparation of samples or patient refusal. Blood sam-
ples were taken 2 days preoperatively. before routine labo-
ratory screening and 2:.7 days after invasive diagnostic
procedures (sample A); between 6 and 60 days (median 7)
postoperatively. immediately before postoperative graft
angiography (sample B); approximately 3 months postoper-
atively at follow-up visit (sample C); and between 222 and
420 days (median 363) postoperatively, before follow-up
graft angiography (sample D). All blood samples were col-
lected and prepared for assay by the same physician
(T.P.G.).
D-dimer studies. The level of D-dimer in 96 citrated
plasma samples collected preoperatively was assayed by the
Dimertest-EIA (Mabco), which uses a monoclonal antibody
specific for the D-dimer plasmin degradation product of
human cross-linked fibrin (26).
Control group. Control samples were obtained in identi-
cal fashion from 51 healthy male and female hospital em-
ployees throughout the course of the study. These control
subjects had not ingested aspirin or other antiplatelet agents
within 7 days before venipuncture and had no known history
or symptoms of cardiovascular disease or any hematologic
disorder.
Graft angiography. Vein graft angiography was per-
formed a median of 7 days (range 6 to 60) after operation in
all 105 patients with adequate blood samples. The transfem-
oral Judkins technique was employed in all cases. The late
vein graft angiogram was performed in 98 patients a median
of 363 days (range 222 to 420) after surgery. There was no
difference in the time to early or late angiography between
the aspirin and placebo groups.
Vein grafts were selectively injected in orthogonal planes
with multiple projections. and angiograms were analyzed by
two independent, blinded observers. A third observer re-
viewed the films in cases ofdisagreement. If the aortic origin
of the graft could not be visualized selectively, biplanar
aortic root angiography was performed. Criteria for graft
occlusion were those previously reported (16). A crude
assessment ofgraft narrowing (diffuse or discrete) was made
from orthogonal spot films of single vein grafts, the caliber at
1 year being compared with that at I week in similar
projection planes. The degree of diffuse narrowing was
recorded as mild «30%), moderate (31% to 70%) or severe
(71% to 99%). The interobserver variability for graft patency
assessed by graft angiography was 4.5%. There was less
agreement, however, in the assessment of stenosis of indi-
vidual grafts, with a variability of 10.3%. The results re-
ported reflect the consensus opinion of two of the three
observers.
Compliance and follow-up. Patients were given a 4 month
supply of the study medication (provided by Bayer Austra-
lia), with tablet record diaries to encourage compliance. At
the first of three follow-up visits, a mid-morning urine
sample was collected and stored at - 20°C for a qualitative
test for salicyluric acid (performed at the end of the study,
using 5% ferric chloride solution to detect aspirin ingested
within the past 12 h) and pill counts were performed.
Patients were given paracetamol as an analgesic to discour-
age inadvertent use of aspirin-containing compounds. Plate-
let aggregation studies (using adrenalin, adenosine diphos-
phate and collagen) were performed for every sixth patient
entered into the trial to further validate compliance.
Clinical data. The baseline clinical characteristics were
obtained by interview with the principal investigator, with
specific details of previous myocardial infarction and anginal
history being recorded from inpatient records, preoperative
cardiac catheterization, electrocardiography at rest and let-
ters from the referring physician. Ongoing data collection
concerning recurrent angina or other thrombotic events
during the first postoperative year was also carried out by
the principal investigator who did not know the patients
allocated study medication.
Data analysis. Data were collated with use of Datastar
(Micropro). Unless stated otherwise, values are expressed
as mean values ± SD. Proportions of placebo and treatment
groups were compared with Fisher's exact test or, where
appropriate, the standard chi-square test (27).
Multivariate logistic regression was performed with the
SPIDA statistical package (28). Occlusion rates were ex-
pressed per patients (with one or more distal anastomoses
occluded) and per distal anastomosis. The analysis of mul-
tiple distal anastomoses in one patient was addressed using a
logistic model, with the distal anastomosis (or graft) as the
observational unit and adjusting for patient-specific and
graft-specific variables according to statistical methods pre-
viously reported (I8).
Beta-thromboglobulin values in the study patients
showed an abnormal distribution, and logarithmic transfor-
mation was required to obtain a normal distribution for
comparative statistical analysis. However, for the presenta-
tion of data in this report, the arithmetic mean values and
standard deviations of the raw data have been used to clarify
the pattern evident among various groups. All analyses and
conclusions arising from this analysis were performed on
logarithmically transformed data. The statistical significance
of changes in the same variable was evaluated with Student's
t test. A p value <0.05 was considered significant.
Results
Patients. A total of 105 patients randomized to receive
either aspirin or placebo were studied with postoperative
graft angiography and had at least a preoperative beta-
thromboglobulin plasma sample prepared; 98 patients com-
pleted the 12 month follow-up study and had three or more
serial blood samples for beta-thromboglobulin assay. Two
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Table 1. Patient Characteristics and Risk Factors
Placebo Aspirin 70
r= 0·65
P<O'0001
AMI = acute myocardial infarction; FH =family history; NYHA = New
York Heart Association.
No.
Mean age (range) (yr)
Male(%)
Female (%)
FH of angina or AMI (%)
Hypertension (%)
Smoking (%)
Angina (NYHA functional class)
lor 11(%)
III or IV (%)
Previous AMI (%)
Serum cholesterol
(mmol/liter) (± SD)
49
56.7 (39-69)
39 (79.6)
10 (\9.6)
31 (63.3)
19 (37.3)
34 (69.4)
29 (59.2)
20 (40.8)
39 (79.6)
7.0 ± 1.3
(n = 25)
56
55.3 (31-69)
47 (83.9)
9 (\6.1)
43 (76.8)
23 (41.1)
38 (67.9)
37 (66.1)
19 (33.9)
47 (83.9)
7.3 ± 1.2
(n = 26)
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Figure 1. Correlation between plasma beta-thromboglobulin (fITG)
levels at 3and 12 months postoperatively in 43 patients.
D) in the 43 patients who had both samples available is
remarkably close, with the exception of 5 patients (p <
0.001, r = 0.65). In both placebo and treatment groups, the
beta-thromboglobulin level tended toward "normal" at 3
and 12 months postoperatively, but these changes were not
significant. However, the reduction in plasma beta-
thromboglobulin from the preoperative level to that at 12
months postoperatively was greater in the aspirin-treated
than in the placebo group when analyzed by the two sample
t test (p < 0.001) (Table 2).
Multivariate logistic regression analysis demonstrated a
significant association between preoperative (sample A)
plasma beta-thromboglobulin concentration and graft occlu-
sion both overall (p < 0.02) and late (p < 0.02). There was no
association found with early graft occlusion (p = 0.44).
There was also no significant association between beta-
thrornboglobulin and serum creatinine, a history of cigarette
smoking, gender, hyperlipidemia or preoperative use of
calcium antagonists or beta-adrenergic blocking agents.
Likewise, a history of previous myocardial infarction from
historical, electrocardiographic (ECG) and ventriculo-
graphic data did not show any correlation with plasma
beta-thromboglobulin concentration. No patients WI e
found to have intracardiac thrombus on the preoperative ft
ventriculogram. There was no association between the pre-
operative beta-thromboglobulin level and the maximum of
four anticardiolipin antibody levels measured in correspond-
ing patients. There was no correlation between preoperative
beta-thromboglobulin levels and D-dimer. Furthermore, no
correlation was found between preoperative beta-thrombo-
globulin level and the number of arteries grafted at surgery.
refused to return for follow-up evaluation after leaving the
hospital, one of whom had a pulmonary embolism on the
17th postoperative day; one patient moved overseas; one
died of carcinoma of the lung; one had a cerebrovascular
accident; and two died suddenly within 3 months of opera-
tion, the cause of death not being ascertained. Of the seven
patients who did not have 12 month angiography, six had A
and B plasma samples available and one had an A sample
only. These are included in the analysis of early graft and
overall graft occlusion.
OJ the 105 patients included in the final analysis, 49
received the placebo and 56 received aspirin. Clinical vari-
ables and risk factors for coronary artery disease were
evenly distributed between the two groups (Table 1). There
were 3.6 distal anastomoses per patient in the placebo group
and 3.4 per patient in the aspirin group. Endarterectomy was
performed in 11% of subjects in the placebo group and 12%
of patients in the aspirin group. A total of 363 distal anasto-
moses were performed overall.
Plasma beta-thromboglobulin. Plasma levels of beta-
thromboglobulin were assayed in 105 preoperative (A), 97 1
week postoperative (B), 59 3 month (C) and 8612 month (D)
samples. Throughout the study, control plasma samples
were prepared from 51 healthy hospital employees, yielding
a mean control value of 22.6 ± 11.1 ng/ml. The preoperative
(sample A) beta-thromboglobulin concentration of 29 ± 13.5
ng/ml for the entire group (n = 105) was significantly higher
than for the control group (p < 0.004).
Postoperatively, beta-thromboglobulin remained compar-
atively constant over the subsequent 12 months (Table 2),
with the exception of sample B, which was almost invariably
elevated further and significantly higher than at other sam-
pling times. The constancy of plasma beta-thromboglobulin
levels in individual patients over time is demonstrated in
Figure 1. The correlation between plasma beta-thromboglo-
bulin assayed at 3months (sample C) and 12 months (sample
o 10 20 30
12 MONTHS
40 50
~TG ng/mL
80 70
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Table 2. Plasma Beta-Thromboglobulin Levels Preoperatively and During 12 Months of Follow-up
Sample A Sample B Sample C Sample D
(n = 105) (n = 97) (n = 59) (n = 86)
Aspirin group
Nonoccluded (n = 49) 29.6 + 14.5 39.4 + 16.4 25.6 + 12.6 24.3 + 10.0
Occluded (n = 7) 30.3 + 13.1 48.9 + 15.4 27.4 + 10.1 28.0 + 10.8
Total (n = 56) 29.7 + 14.2* 40.5 + 16.4 25.9 + 12.1 24.7 + 10.1*
Placebo group
Nonoccluded (n = 32) 24.2 + 9.0 41.8 + 19.5 27.4 + 8.4 25.1 + 9.2
Occluded (n = 17) 35.8 + 15.2 51.7 + 28.3 29.3 + 12.7 31.4 + 11.1
Total (n = 49) 28.2 + 12.6* 45.3 + 23.1 27.9 + 9.5 27.5 + 10.3*
*Aspirin (total samples A-D) versus placebo (total samples A-D) p< 0.001, see text. Values are arithmetic mean values + SD. Sample Awas collected 2
days preoperatively, sample Bat 7days. sample C at 3months and sample Dat 12 months postoperatively.
Graft occlusion
No. of patients
Early 6 3
Late 10 4
Early and late I
Total (%) 17 (34.7) 7(12.5)
Graft occlusion
Distal anastomoses
Early 9 4
Late 15 5
Total(%) 24 (13.6) 9(4.7)
Graft stenosis
None or mild (00/0--30%) 60 (74.1) 74 (79.6)
Moderate (310/0--70%) 18 (22.2) 17 (18.3)
Severe (710/0--99%) 3(3.7) 2(2.1)
When stenosis of single vein grafts was assessed on the 1
year angiogram, no association was found between severity
of graft narrowing and beta-thromboglobulin level.
Placebo group. Of the 49 patients in this group, 17
(34.7%) had one or more graft occlusions (Table 3), 6 early,
10 late and 1 with both an early and a late occlusion,
Analysis of preoperative beta-thromboglobulin data in the
placebo group (Fig, 2) revealed a significant difference in the
preoperative beta-thromboglobulin level between those with
graft occlusion (35.8 ± 15,2 ng/ml, n = 17) and those without
graft occlusion (24.2 ± 9.0 ng/ml, n = 32) (p < 0.03).
Aspirin group. Of the 56 aspirin-treated patients, 7
(12.5%) had one or more graft occlusions, 3 early and 4 late.
There was no significant correlation between the preopera-
tive plasma beta-thromboglobulin concentration and graft
occlusion in the aspirin-treated group (Fig. 2). The effect of
aspirin treatment on the coronary artery bypass graft occlu-
sion rate was significant (p < 0.005). When the numbers of
patients with graft occlusion are divided into early and late
occlusions and the effects of beta-thromboglobulin level
(preoperative sample) and treatment with aspirin are ana-
Table 3. Graft Occlusions and Stenosis
Placebo Group Aspirin Group
lyzed by logistic regression, the following associations were
found: late graft occlusion was significantly associated with
the preoperative beta-thromboglobulin level (p < 0.02), and
aspirin treatment was effective in preventing occlusion when
adjusted for the preoperative beta-thromboglobulin level (p
< 0.005).
Distal anastomoses. A similar reduction in occlusion rate
was achieved with aspirin when total distal anastomoses
were analyzed (Table 3).
Endarterectomy. The performance of endarterectomy
was associated with an independent risk of graft occlusion; 9
of 23 patients had graft occlusion compared with 15 of 82
patients in whom endarterectomy was not performed (p <
0.035). The preoperative beta-thromboglobulin level in pa-
tients who underwent endarterectomy was not significantly
different from that in those not requiring endarterectomy
(29.5 ± 12.1 versus 28.9 ± 13.9 ng/ml, respectively).
Thrombotic events. Postoperative thrombotic events
(pulmonary embolism, myocardial infarction, cerebrovascu-
lar accident, sudden death and peripheral arterial embolism)
occurred in similar proportions of the aspirin-treated (16.1%)
and placebo (12.2%) groups. The preoperative beta-
thromboglobulin level in these 15 patients was not signifi-
cantly different from that in the remaining study patients.
D·dimer assay. Plasma samples for D-dimer assay were
collected in 96 patients preoperatively (sample A). Control
samples were collected from 45 healthy hospital employees
throughout the study. Preoperatively, both treatment groups
had significantly higher levels (108 ± 183.9 ng/m!) than those
of the control group (64.3 ± 61.85 ng/m!) (p < 0.03). The
preoperative D-dimer level in patients who subsequently
developed graft occlusion was not significantly different
from that of patients who did not.
Compliance. On the basis of urine tests, pill counts and
tablet record diary entries, 94% of patients took 2:95% of
their medications and 2% took <90%. A test for urinary
salicyluric acid was positive in 90% of the aspirin-treated
group and 3% of the placebo group. Platelet aggregation
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studies showed a full "aspirin defect" in all six patients from
the treated group and in one of nine from the placebo group.
Side effects. Administration of the study medication co-
incided with hematemesis in one patient (aspirin group) 2
weeks postoperatively, necessitating blood transfusion.
There was no significant difference between the aspirin and
placebo groups in blood loss over the first 24 h (552 ± 336
versus 475 ± 223 ml) or total blood loss (698 ± 451 versus
592 :t 236 mI). Three of 56 patients receiving aspirin had
immediate reoperation for bleeding compared with none of
49 patients taking placebo. In each case, a surgically cor-
rectable cause of bleeding was identified.
Complications occurred in three patients during early
postoperative angiography, but there were no significant
complications during the 1 year study. Early complications
comprised a "shower" of peripheral emboli in the right foot
in one patient (treated successfully with intravenous hepa-
rinization), traumatic dissection of proximal graft anastomo-
sis in one patient (asymptomatic) receiving aspirin (treated
as an occlusion in the data analysis) and severe allergic
reaction to meglutamine diatrizoate (resolving promptly with
fluid replacement, antihistamine and hydrocortisone intrave-
nously). There were no permanent sequelae from these
complications.
Figure 2. The preoperative beta-thromboglobulin ({ITO) levels in
patients subdivided according to treatment (aspirin [n = 56] or
placebo [n = 49]) and the presence or absence of graft occlusion.
Mean values ± SD are represented by solid bars. The mean ± SD
beta-thromboglobulin levels of the control group are presented on
the right of the figure.• = nonocclusion; A = occlusion.
Discussion
Plasma beta-thromboglobulin and graft occlusion. rFrom
this study, elevated preoperative plasma beta-thromboglob-
ulin concentration is significantly correlated with occlusion
of saphenous vein bypass grafts during the first postopera-
tive year. When the placebo group is analyzed separately,
there is an even clearer association between the preoperative
beta-thromboglobulin level and the incidence of subsequent
graft occlusion (Fig. 2).
Effect of aspirin on graft occlusion. Aspirin was highly
protective of graft patency, reducing the proportion of
patients with graft occlusion from 34.7% to 12.5%. This
benefit was more apparent in patients with higher beta-
thromboglobulin levels. Earlier reports have shown that
aspirin (17,18,20) and other antiplatelet agents (16) improve
early graft patency when administration of the drug is
commenced either preoperatively or in the early postopera-
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tive period. Three patients in this study required reoperation
and were found to have a surgically correctable cause for
bleeding, even though they were in the aspirin-treated group.
The beneficial effect of once daily aspirin was also main-
tained when patency rates at late vein graft angiography
were assessed. In a recent report (20) comparing several
antiplatelet regimens for coronary artery bypass surgery, a
cumulative patency rate for all three aspirin-treated groups
was needed to show a significant benefit compared with
placebo at late angiography.
Beta-thromboglobulin levels: effects of surgery and aspirin.
Preoperatively, the mean beta-thromboglobulin level in the
study patients with coronary artery disease was significantly
higher than that in the control group. Factors associated with
increased beta-thromboglobulin (lipidemia and left ventricu-
lar thrombosis) showed no significant correlation with beta-
thromboglobulin levels in this study. Patients with significant
renal impairment, which may contribute to high levels of
beta-thromboglobulin, were excluded according to the pro-
tocol. The preoperative beta-thromboglobulin level in pa-
tients with unstable angina was not significantly higher than
that in those with class I or II angina, although there were
only a few patients in the former category. Although these
results are in accord with several previous studies (2,3,6)
showing elevated beta-thromboglobulin in patients with cor-
onary disease, other centers (15) have shown conflicting
results. Also, a similar lack of agreement is encountered in
studies of platelet survival time in patients with coronary
disease. Although there are several reports (8,10) of short-
ened platelet survival in patients with coronary artery dis-
ease, other centers (14) have reported no significant differ-
ence from values in the normal population. Reasons for this
discrepancy may well reflect differences in techniques for
measuring platelet survival in vivo and in the collection,
preparation and assay of plasma for beta-thromboglobulin.
The postoperative beta-thromboglobulin (sample B) level
was significantly higher than the preoperative and late
postoperative levels in all subgroups. Blood was collected
immediately before the early angiogram and as late as
possible after any invasive vascular procedure. This higher
level most likely reflects the combined influences of the
cardiopulmonary bypass pump on the circulating platelet
pool and the effects of major surgery, as well as the frequent
need for intravenous therapy and venipuncture in the first
week postoperatively. There was a trend toward a decrease
in late postoperative beta-thromboglobulin levels in both
groups, the trend being more apparent in the aspirin-treated
group, although this did not reach significance. Despite this,
the overall decrease in beta-thromboglobulin over 12 months
was significantly greater in patients receiving aspirin than in
those receiving placebo (p < 0.001). This trend is in accor-
dance with the findings of an earlier study (3) in which
sulfinpyrazone rather than aspirin was employed. A signifi-
cant reduction in plasma beta-thromboglobulin concentra-
tion as a result of aspirin treatment in patients with periph-
eral vascular disease was recently reported (29). The
decrease in beta-thromboglobulin was associated with an
increase in platelet survival time in both these studies (3,29).
In this prospective study, we observed a significant
correlation between elevated plasma beta-thromboglobulin
level and a thrombotic event (graft occlusion). Those who
developed graft occlusion in the placebo group had the
highest mean preoperative beta-thromboglobulin concentra-
tion of all subgroups. Although this does not provide un-
equivocal evidence of a cause and effect relation between
beta-thromboglobulin and graft occlusion, the inference
could be drawn that patients with biochemical evidence of
greater platelet activation have a systemic predisposition to
develop thombosis. Thus, we may be able to identify a
subgroup at greater risk of graft occlusion, even though
factors such as local anatomy, blood flow and other vasoac-
tive substances will also modify the platelet-vessel wall
interaction. Although elevated beta-thromboglobulin is pre-
dictive of subsequent graft occlusion, a similar pattern was
not observed with respect to other thrombotic events during
or after surgery.
Pathogenesis of graft occlusion. The pathogenesis of vein
graft narrowing after aortocoronary bypass surgery involves
a diffuse intimal hyperplasia that has been postulated to be
related to the mitogenic effects of platelet-derived growth
factor (23). Antiplatelet therapy has been reported (23) to
have minimal effect on the severity of this process, and our
data support this finding.
Elevated anticardiolipin antibodies have been reported
(30) to be associated with a higher rate of thrombotic events
in younger men after myocardial infarction. One postulated
mechanism to explain this association was that anticardio-
lipin antibodies cause continuing platelet activation by cross-
reacting with antigenically similar phospholipids in the plate-
let cell wall, predisposing to thrombosis. In an analysis of the
first 83 patients entered into this study (24), we reported a
strong association between elevated anticardiolipin antibod-
ies and bypass graft occlusion. However, in this study, we
have been unable to show any correlation between anticar-
diolipin and beta-thromboglobulin levels. The poor correla-
tion between these two markers of thrombotic tendency and
clinical events reflects the multifactorial nature of the inter-
action of platelets, blood and vessel wall, resulting in throm-
bosis.
The D-dimer is a relatively new immunoassay to detect
the degradation products of cross-linked fibrin (26). Ele-
vated levels have been reported in patients with pathologic
fibrinolysis (31) and after intravenous streptokinase therapy
for acute myocardial infarction (32). In this study, patients
with coronary artery disease were found to have higher
D-dimer levels than in the normal population. The preoper-
ative D-dimer level was not significantly different between
patients with patent or occluded grafts. These data may
lACC Vol. 15, No.6
May 1990:1250-8
GAVAGHAN ET AL.
ASPIRIN FOR BETA-THROMBOGLOBULIN IN GRAFT OCCLUSION
1257
conceivably reflect a delicate equilibrium between ongoing
local thrombosis and endogenous thrombolysis within an
atherosclerotic coronary system.
Limitations of the study. Plasma samples were collected
and prepared for assay by the same physician throughout the
study to achieve a high degree of consistency in technique
and minimize in vitro release of platelet secretory proteins.
It has been suggested (33) that simultaneous assay of both
beta-thromboglobulin and platelet factor 4 is necessary to
allow distinction between in vivo and artifactual in vitro
release. We assayed for beta-thromboglobulin alone in this
study and excluded from analysis six disproportionately
elevated beta-thromboglobulin levels, each> 100 ng/ml. The
decision to exclude these elevated levels was based on the
presumption that because all six levels were in excess of 4
SD of their respective group mean values (after logarithmic
transformation), they reflected aberrant or artifactual in vitro
release. Such extreme data would distort rather than clarify
the meaningful interpretation of these results. The high
degree of reproducibility over time of consistent beta-
thromboglobulin levels within 43 individual study patients
(Fig. 1) further emphasizes the aberrancy of these very
elevated levels.
Conclusions. Our data support the contention that pa-
tients with coronary atherosclerotic disease have signifi-
cantly increased platelet activation. Whether this is a cause
or effect of the atherosclerotic plaque remains unclear.
However, we have prospectively shown a strong association
between a biochemical index of excessive platelet activation
and subsequent graft occlusion. Importantly, aspirin (324
mg/day) given early after bypass surgery provides significant
protection against vein graft occlusion during the first year
after operation. Aspirin is associated with a greater reduc-
tion of indexes of platelet activation than is bypass surgery
alone and may afford protection against various clinically
relevant thrombotic events.
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